ArticleBMC cancer2025
Methionyl-tRNA synthetase 1 expression, the possibility as a diagnostic and prognostic factor in papillary thyroid cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethionyl-tRNA synthetase 1 (MARS1) is a critical enzyme in translation initiation, responsible for catalyzing the transfer of Met to the initiator tRNA. In this study, we aimed to examine whether MARS1 expression is different between normal follicular cells and papillary thyroid carcinoma (PTC) cells in thyroid tissue and whether it can supplement the limitations of general cell staining methods currently performed for diagnosis of PTC.
methodsInitially, 103 patients were included to compare MARS1 expression in PTC and normal follicular cells. Next, 100 patients were selected to compare MARS1 expression using immunohistochemical analysis in patients with (n = 50) and without (n = 50) lateral neck metastasis.
resultsThe average MARS1 expression grade of PTC cells was 2.59 and that of normal follicular cells was 1.28. MARS1 expression in the two groups showed significant differences (p < 0.001). There was a significant difference in the average MARS1 expression grade of PTC cells between the metastasis and non-metastasis groups (p < 0.05). Additionally, a significant difference was observed in the average MARS1 expression grade between the lymph node of the metastasis group and PTC cells of the non-metastasis group (p < 0.05).
conclusionsOur analyses suggest that MARS1 could be used as a complementary method to the current fine needle aspiration biopsy tissue staining method. Additionally, MARS1 could be a predictor of the prognosis of PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.